Bio-Connect

LZTS1 antibody [C1C3]

GTX117376
GeneTex
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
ReactivityHuman
TargetLZTS1
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    LZTS1 antibody [C1C3]
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 1:500-1:3000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
  • Certification
    Research Use Only
  • Clonality
    Polyclonal
  • Concentration
    0.61 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID11178
  • Target name
    LZTS1
  • Target description
    leucine zipper tumor suppressor 1
  • Target synonyms
    F37; F37/Esophageal cancer-related gene-coding leucine-zipper motif; FEZ1; leucine zipper putative tumor suppressor 1; leucine zipper, putative tumor suppressor 1
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ9Y250
  • Protein Name
    Leucine zipper putative tumor suppressor 1
  • Scientific Description
    This gene encodes a tumor suppressor protein that is ubiquitously expressed in normal tissues. In uveal melanomas, expression of this protein is silenced in rapidly metastasizing and metastatic tumor cells but has normal expression in slowly metastasizing or nonmetastasizing tumor cells. This protein may have a role in cell-cycle control by interacting with the Cdk1/cyclinB1 complex. This gene is located on chromosomal region 8p22. Loss of heterozygosity (LOH) in the 8p arm is a common characteristic of many types of cancer. [provided by RefSeq]
  • Reactivity
    Human
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203

References

  • LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. Lovat F et al., 2014 Feb 28, Oncotarget
    Read more